Skip to content

Improving Female Sexual Wellness

Effect of Commercial Genital Vibrators Use on Female Wellness

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04824820
Enrollment
86
Registered
2021-04-01
Start date
2021-04-10
Completion date
2023-04-05
Last updated
2023-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sexuality, Sexual Dysfunction, Sexual Desire Disorder, Hypoactive Sexual Desire Disorder, Orgasmic Disorder, Pelvic Organ Prolapse, Urinary Incontinence, Interstitial Cystitis, Pelvic Floor Disorders, Female Sexual Dysfunction

Keywords

sexuality, Sexual Dysfunction, Sexual Desire Disorder, Hypoactive Sexual Desire Disorder, Orgasmic Disorder, Pelvic Organ Prolapse, Urinary Incontinence, Interstitial Cystitis, Pelvic Floor Disorders, Wellness, Female Sexual Dysfunction

Brief summary

The purpose of this study is to assess the effect of commercially available genital vibrator use on sexual health, female pelvic floor disorders, and overall quality of life among a diverse population of women.

Interventions

BEHAVIORALVibrator

Clitoral stimulation

Sponsors

Cedars-Sinai Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* English speaking * Diagnosis of female sexual dysfunction, pelvic floor dysfunction, genito-urologic issues (stress urinary incontinence, urge urinary incontinence, pelvic organ prolapse, interstitial cystitis, pelvic pain, dyspareunia, lichen sclerosis) * Manual dexterity to use vibrator

Exclusion criteria

* Non English speaking * Pregnancy or \<12 months postpartum * Poor manual dexterity

Design outcomes

Primary

MeasureTime frameDescription
To assess the change from baseline sexual function at 3 monthbaseline, post intervention at 3 monthsAssessment based on validated questionnaire. Female Sexual Function Index (FSFI), a 19-item measure of sexual function in all four domains: desire, arousal, orgasm and sexual pain. The total score ranges from 0-36, with higher scores indicating better sexual function. Total score below 26.6 indicates clinical Female Sexual Dysfunction (FSD).
To assess the change from baseline degree of pelvic organ prolapse at 3 monthbaseline, post intervention at 3 monthsThe Pelvic Organ Prolapse Quantifications System (POP-Q) is a system for assessing the degree of prolapse of pelvic organs to help standardize diagnosing, comparing, documenting, and sharing of clinical findings. This assessment is the most frequently used among research publications related to pelvic organ prolapse.
To assess the change from baseline overall health and quality of life at 3 monthbaseline, post intervention at 3 monthsSelf-reported quality of life (SF-12) is a general health measure assessing the impact of health on an individual's everyday life. The SF-12 consists of eight domains and generates two separate summary scores, physical functional scores (PCS) and mental function scores (MCS), ranging from 0 to 100. Higher scores indicated better health related quality of life.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026